## CAH: Cardinal Health, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.0% below STRENGTH zone (3.0-6.0%); PEG 1.89 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($197.93)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Did Cardinal Health’s Strong Quarter and Specialty Push Just Shift CAH’s Investment Narrative?**
- Source: Simply Wall Street | 20251220T192754 | Bullish | Relevance: 100%
- Cardinal Health recently reported a strong quarter, exceeding revenue and EPS expectations, driven by operational strength and strategic focus on specialty therapies and nuclear medicine. This performance and management's optimistic outlook could redefine the company's investment narrative, emphasizing growth in higher-value areas despite ongoing regulatory risks. The company's forecasts project significant revenue and earnings growth by 2028, suggesting a fair value of $216.60 per share.

**2. Wedge Capital Management L L P NC Sells 37,487 Shares of Cardinal Health, Inc. $CAH**
- Source: MarketBeat | 20251221T123554 | Somewhat-Bullish | Relevance: 100%
- Wedge Capital Management L L P NC reduced its stake in Cardinal Health, Inc. by 18.9% during the third quarter, selling 37,487 shares and leaving it with 161,185 shares valued at approximately $25.3 million. Despite this sale, analysts maintain a "Moderate Buy" rating for Cardinal Health with an average price target of $209, and the company recently surpassed revenue and EPS estimates while announcing a quarterly dividend of $0.5107. Institutional investors collectively own 87.17% of the stock, with several other funds increasing their positions in CAH.

**3. Did Cardinal Health’s Strong Quarter and Specialty Push Just Shift CAH’s Investment Narrative?**
- Source: Simply Wall Street | 20251220T190751 | Bullish | Relevance: 100%
- Cardinal Health recently reported a strong quarter, exceeding revenue and EPS expectations, driven by broad operational strength and an emphasis on higher-value areas like specialty therapies and nuclear medicine. This performance and management's optimistic outlook aim to reshape the investment narrative by highlighting growth in specialized segments, despite ongoing regulatory risks concerning drug pricing. The company's strategy focuses on leveraging its distribution scale into more stable, higher-margin businesses.

**4. |Voya Investment Management LLC Has $128.98 Million Stock Holdings in Cardinal Health, Inc. $CAH**
- Source: MarketBeat | 20251220T140736 | Somewhat-Bullish | Relevance: 100%
- |Voya Investment Management LLC significantly increased its stake in Cardinal Health, Inc. (NYSE:CAH) by 298.3% in the third quarter, bringing its total holdings to 821,723 shares valued at approximately $128.98 million. Other institutional investors also adjusted their positions, collectively owning 87.17% of the company's stock. Cardinal Health reported strong earnings and revenue for the quarter, exceeding analyst expectations, and announced a quarterly dividend of $0.5107 per share.

**5. McKesson Stock: I Expect A Significant Slowdown In 2026 (NYSE:MCK)**
- Source: Seeking Alpha | 20251221T152830 | Neutral | Relevance: 75%
- McKesson experienced impressive growth in 2025, driven by GLP-1 drug tailwinds, but this momentum is expected to fade, leading to a significant slowdown in 2026. Despite strong top-line growth, the company's margin profile remains lackluster, and its valuation at 21x forward earnings suggests potential multiple contraction. The author maintains a bearish outlook on the stock.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $243 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 11 ($0.00M) |
| Sells | 5 ($0.41M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Blackrock Inc.: 13.2% (+3.0%)
- Vanguard Group Inc: 13.0% (+0.8%)
- State Street Corpora: 5.2% (-3.0%)
- Geode Capital Manage: 2.7% (+1.5%)
- Wellington Managemen: 2.4% (+153.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +1.1% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.89 elevated, pricing in significant growth expectations. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $48.8B |
| Beta | 0.64 |
| 52W Range | $116.69 - $214.93 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.89 |
| Forward P/E | 18.5 |
| Current P/E | 20.9 |
| YoY Growth | 12.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 0.9% to 2.0% (+1.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.0pp (needs >3.0% for momentum thesis). MRS_5 at 0.8% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.76), momentum weakening. OFD pattern: +MLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.03% (CS: 82) | Neutral |
| RSI_14 | 64.4 | Neutral |
| MACD Histogram | -0.76 | Bearish |
| vs SMA20 | 1.012x | Above |
| vs SMA50 | 1.075x | Above |
| vs SMA200 | 1.283x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $205.17
- **Stop Loss:** $197.93 (3.5% risk)
- **Target:** $212.41 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 165
- **Position Value:** $33,853.05
- **Portfolio %:** 33.85%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-01-29 (Est: $2.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.17 | $2.55 | +17.3% |
| 2025Q2 | $2.03 | $2.08 | +2.4% |
| 2025Q1 | $2.15 | $2.35 | +9.4% |
| 2024Q4 | $1.76 | $1.93 | +9.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*